Amneal Pharmaceuticals (AMRX) Operating Leases (2019 - 2026)

Amneal Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $41.1 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 79.84% year-over-year to $41.1 million in Q1 2026; TTM through Mar 2026 was $41.1 million, a 79.84% increase from a year earlier, with the FY2025 full-year figure at $14.2 million, down 69.82% from the prior year.
• Operating Leases climbed to $41.1 million in Q1 2026 per AMRX's latest filing, from $14.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $59.2 million in Q4 2022 and bottomed at $10.3 million in Q3 2024.
• The 5-year median for Operating Leases is $26.4 million (2025), against an average of $27.5 million.
• Biggest YoY gain for Operating Leases was 157.23% in 2025; the steepest drop was 69.82% in 2025.
• Year by year, Operating Leases stood at $59.2 million in 2022, then retreated by 17.42% to $48.9 million in 2023, then dropped by 3.84% to $47.0 million in 2024, then plunged by 69.82% to $14.2 million in 2025, then jumped by 189.55% to $41.1 million in 2026.
• Per Business Quant, the three latest AMRX Operating Leases figures stand at $41.1 million (Q1 2026), $14.2 million (Q4 2025), and $26.4 million (Q3 2025).